Skip to main content
. 2016 Jun 21;22(23):5384–5392. doi: 10.3748/wjg.v22.i23.5384

Table 3.

Type of recurrence

Type of recurrence Sorafenib Control P value1
Hepatic 8 28 0.079
Extrahepatic 5 12 0.707
Hepatic + extrahepatic 2 11 0.142
Overall hepatic recurrence 10 39 0.008
Overall extrahepatic 7 23 0.167
Total recurrence 15 (44.1%) 51 (75.0%) 0.002
1

Study group compared with control group.

HHS Vulnerability Disclosure